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ractional Flow Reserve
New Set of Lenses
or the Occulostenotic Reflex?*
. Michael Gibson, MS, MD, Duane Pinto, MD, MPH
oston, Massachusetts
ultivessel coronary artery disease is frequently encoun-
ered during cardiac catheterization of patients with acute
oronary syndromes (1,2). Current guidelines from the
merican College of Cardiology/American Heart Associa-
ion and European Society of Cardiology discourage treat-
ent of non-infarct-related arteries during primary percu-
aneous coronary intervention (PCI) or rescue PCI in
emodynamically stable ST-segment elevation myocardial
nfarction (STEMI) patients (3,4). Despite the fact that it is
Class III contraindication, PCI of a nonculprit artery is
erformed in approximately 1 of 10 patients during primary
CI and is associated with a doubling of mortality at 90
ays (5). Although multivessel intervention in STEMI
atients who are hemodynamically stable may be associated
ith worse clinical outcomes, multivessel intervention dur-
ng unstable angina/non-STEMI (NSTEMI) has been
ssociated with outcomes similar to that associated with
ingle-vessel intervention (2,6).
See page 1274
Residual ischemia in nonculprit lesions can obviously be
afely assessed in a noninvasive fashion at a later time. Early
n, however, during cardiac catheterization for the index
vent, the observant interventional cardiologist is often
empted to intervene immediately to treat additional flow
bnormalities in the nonculprit territory. Indeed, multiple
tudies involving thousands of STEMI patients have dem-
nstrated that basal blood flow in nonculprit arteries is
lowed by 45% at the time of STEMI, and this may, in turn,
aise questions as to whether interventional cardiologists
hould urgently interrogate and immediately treat hemody-
amically significant nonculprit lesions identified at the
ime of the index event. This desire to intervene urgently
hould be tempered, however, by the observation that
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Department of Medicine, Cardiovascular Division, Beth Israel Deacon-r
ss Medical Center, Boston, Massachusetts. Drs. Gibson and Pinto report that they
ave no relationships to disclose.esions may regress as spasm resolves (7) and abnormality in
onculprit flow is transient, generally normalizing over the
ext day. Both alpha-blockers (8) and PCI of the culprit
rtery (9,10) may improve flow in the nonculprit artery.
hese observations may reflect the role of heightened
ascular tone in shared microvascular territories of the
ulprit/nonculprit arteries or edema as the underlying mech-
nism. Thus, abnormal flow in the nonculprit territory may
e an epiphenomenon or an acausal correlate of adverse
utcomes and may not be the valid target of an urgent PCI.
The interpretation of measurements of fractional flow
eserve (FFR) in STEMI patients is likewise complex: the
alues in STEMI patients are elevated compared with FFR
alues in arteries from patients with angina, and FFR values
re higher among patients with Thrombolysis In Myocar-
ial Infarction (TIMI) flow grade 2 compared with TIMI
ow grade 3 (11). These findings imply that increased
icrovascular resistance and dysfunction may lead to an
lteration in flow dynamics associated with a smaller pres-
ure drop across the stenosis than would normally be
xpected and thus a higher FFR. Various other imaging
odalities such as angiography (12,13), myocardial contrast
chocardiography (14), magnetic resonance imaging (15),
nd positron emission tomography (16) have demonstrated
icrovascular dysfunction during infarction.
In this issue of JACC: Cardiovascular Interventions, a
roup of patients with both NSTEMI and STEMI under-
ent FFR measurement of the nonculprit artery during PCI
17). This analysis demonstrated no change in FFR at
aseline compared with a follow-up of 35  4 days. In only
of 112 stenoses measured in 101 patients (75 STEMI, 26
STEMI) did the FFR decline from more than 0.80 at
aseline to 0.75 at follow-up. Although these findings
upport the feasibility and stability of FFR measurements
btained during acute coronary syndromes, important ques-
ions remain regarding if and how these measurements
hould inform clinical decision making.
There is ongoing debate surrounding the merits of
ulprit-only revascularization versus complete multivessel
evascularization at the time of the index PCI versus staged
evascularization at a later date. Although several very small
andomized studies indicate that complete revascularization
either immediate or staged) reduces the need for subse-
uent revascularization, there does not appear to be a
eduction in cardiac death or MI associated with complete
evascularization (18). Whereas the lack of an improvement
n death and MI associated with complete revascularization
rgues against the need for FFR assessment of nonculprit
essels, it could also be argued that FFR assessment could
iscriminate high-risk lesions that are more appropriate for
evascularization from those that do not warrant interven-
ion. If FFR did identify those vessels and patients who
ould derive selective benefit from revascularization, then
outine application of FFR might improve the efficiency of
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1283linical care by obviating the need to evaluate these lesions
ither invasively or noninvasively later. For NSTEMI pa-
ients, FFR measurements may be beneficial in avoiding
evascularization of arteries that are not flow-limiting. As
ome of the investigators of this study showed, guiding PCI
n multivessel disease is improved with FFR (19), and 20%
f lesions may not be flow-limiting even when angiographic
stimates classify them as between 71% and 90% (20).
This study is valuable in that it demonstrates the feasi-
ility of interrogating nonculprit arteries during acute cor-
nary syndromes, but the limited sample size is insufficient
o exclude a potential hazard of instrumenting nonculprit
rteries in a thrombotic milieu. Although the present study
emonstrates that hemodynamically significant lesions can
e identified during index procedure, it does not shed light
n whether the identification and PCI of these higher-risk
esions as part of an immediate or staged complete revascu-
arization strategy could further guide targeted intervention
nd further improve clinical outcomes. Additional questions
nclude whether early invasive interrogation of nonculprit
esions via FFR could obviate the need to perform a
oninvasive stress test at a later date, and if so, is nonculprit
FR assessment during the index procedure cost-effective.
Perhaps the greatest value of FFR, however, lies instead
n identifying those nonculprit lesions that clearly do not
arrant intervention. Only randomized trials of an FFR-
uided strategy to identify patients who require only culprit
evascularization could fully evaluate whether FFR is just
hat the doctor ordered: a very effective lens for the
occulostenotic reflex” rather than a trigger for complete
evascularization.
eprint requests and correspondence: Dr. C. Michael Gibson,
epartment of Medicine, Cardiovascular Division, Beth Israel
eaconess Medical Center, 185 Pilgrim Road, Boston, Massachu-
etts 02115. E-mail: mgibson@perfuse.org.
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